MAP2K7 and melanoma: In the treatment of BRAF V600 mutant melanoma, the combination of MEK and BRAF inhibition achieved better outcome than used alone, with manageable safety profiles and lower rates of hypoproliferative skin toxicities and musculoskeletal complaints than BRAF inhibitors, and has become the standard of therapy [157, 159].